Related Experiment Video
Updated: Sep 1, 2025

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation
Published on: April 3, 2017
Overexpressed PKM2 promotes macrophage phagocytosis and atherosclerosis
Xiaochen Gai1, Fangming Liu1, Yuting Wu1
1State Key Laboratory of Medical Molecular Biology, Department of Physiology, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background:
The expression of pyruvate kinase muscle 2 (PKM2) is augmented in macrophages of patients with atherosclerotic coronary artery disease. The role of PKM2 in atherosclerosis is to be determined.
Methods:
Global and myeloid cell-specific PKM2 knock-in mice with ApoE-/- background (ApoE-/- , PKM2KI/KI and Lyz2-cre, ApoE-/- , and PKM2flox/flox ) were produced to evaluate the clinical significance of PKM2 in atherosclerosis development. Wild-type and PKM2 knock-in macrophages were isolated to assess the function of PKM2 in macrophage phagocytosis. Atherosclerotic mice were treated with PKM2 inhibitor shikonin (SKN) to evaluate the therapeutic potential of PKM2 suppression in atherosclerosis.
Results:
Oxidized low-density lipoprotein (oxLDL) upregulated PKM2 in macrophages. PKM2 in return promoted the uptake of oxLDL by macrophages. Overexpressed PKM2 accelerated atherosclerosis in mice. SKN blocked the progress of mouse atherosclerosis.
Conclusions:
PKM2 accelerates macrophage phagocytosis and atherosclerosis. Targeting PKM2 is a potential therapy for atherosclerosis.
Insights
Pyruvate kinase muscle 2 (PKM2) fuels macrophage activity and atherosclerosis. Inhibiting PKM2 offers a potential therapeutic strategy for treating this cardiovascular disease.
Area of Science:
- Biochemistry
- Immunology
- Cardiovascular Research
Background:
- Pyruvate kinase muscle 2 (PKM2) expression is elevated in macrophages of patients with atherosclerotic coronary artery disease.
- The specific role of PKM2 in the development of atherosclerosis remains to be elucidated.
Purpose of the Study:
- To investigate the functional role of PKM2 in macrophage phagocytosis and its contribution to atherosclerosis.
- To evaluate the therapeutic potential of targeting PKM2 in a mouse model of atherosclerosis.
Main Methods:
- Generated global and myeloid cell-specific PKM2 knock-in mice on an ApoE-/- background.
- Assessed macrophage phagocytosis in wild-type and PKM2 knock-in macrophages.
- Administered the PKM2 inhibitor shikonin (SKN) to atherosclerotic mice.
Main Results:
- Oxidized low-density lipoprotein (oxLDL) increased PKM2 expression in macrophages, which in turn enhanced oxLDL uptake.
- Overexpression of PKM2 accelerated atherosclerosis progression in mice.
- Shikonin treatment effectively inhibited the progression of atherosclerosis in mice.
Conclusions:
- PKM2 plays a critical role in promoting macrophage phagocytosis and accelerating atherosclerosis.
- Targeting PKM2 represents a promising therapeutic avenue for managing atherosclerosis.
More Related Videos
Related Concept Videos
Inflammation
Atherosclerosis I: Introduction
Coronary Artery Disease II: Pathophysiology
cAMP-dependent Protein Kinase Pathways
Abnormal Proliferation

